- Home
- MRNA vs OWL Comparison
MRNA vs OWL Comparison
Compare MRNA & OWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRNA | OWL |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 9.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRNA | OWL |
|---|---|---|
| Price | $51.78 | $15.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $32.75 | $21.70 |
| AVG Volume (30 Days) | ★ 11.8M | 10.4M |
| Earning Date | 02-13-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 5.71% |
| EPS Growth | N/A | ★ 47.85 |
| EPS | N/A | ★ 0.08 |
| Revenue | $2,232,000,000.00 | ★ $2,745,943,000.00 |
| Revenue This Year | N/A | $18.19 |
| Revenue Next Year | $3.18 | $19.13 |
| P/E Ratio | ★ N/A | $203.26 |
| Revenue Growth | N/A | ★ 27.24 |
| 52 Week Low | $22.28 | $13.25 |
| 52 Week High | $50.00 | $26.73 |
Technical Indicators
Market Signals| Indicator | MRNA | OWL |
|---|---|---|
| Relative Strength Index (RSI) | 82.55 | 51.28 |
| Support Level | $39.21 | $15.27 |
| Resistance Level | $41.98 | $16.11 |
| Average True Range (ATR) | 2.93 | 0.56 |
| MACD | 1.57 | 0.01 |
| Stochastic Oscillator | 87.75 | 60.09 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About OWL Blue Owl Capital Inc.
Blue Owl Capital is one of the world's largest alternative-asset managers, $295.6 billion in total managed assets, including $183.8 billion in fee-earning AUM, at the end of September 2025. The company has three core business segments: global private equity, (with $68.8 billion in total AUM and $40.2 billion in fee-earning AUM), private credit ($152.1 billion/$97.3 billion), and real estate/real assets ($74.7 billion/$46.3 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). The firm operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.